Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
about
Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsPharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsIn vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in SpainSafety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.Tigecycline: a new glycylcycline for treatment of serious infections.Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.Tigecycline: a novel glycylcycline antibiotic.Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal proteins and rRNA.Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control
P2860
Q29398341-7AD04840-F665-4C6C-85BD-B0A4FF2BEC5FQ33722056-658F4950-5CAC-41B4-93D7-62295345067FQ34113886-938DA686-13C2-4E4D-AC7A-53E16B16AB1CQ34123811-6F71A80C-3117-467C-8F41-B105146448C7Q34822277-2447884F-84FA-4C0E-8B54-275699055DDEQ35637071-40C06C73-B49A-4140-8B33-9936C58EB5EAQ35758970-85451A38-2A56-4F1C-8209-6B8BBECC7517Q36218312-4E4B98A3-ADAC-47A8-BC40-5475DE1A3E33Q36312071-07649509-5541-4CD9-8410-86DF05925093Q36379330-6B801505-0411-4001-AE9C-D6A92F3080C8Q37144834-F03DED68-0C69-4A4C-8902-8A1217B241AEQ37608268-3B58D212-E27A-4DED-B895-59AFF3FEFAB1Q39730764-8C0D12A9-7BD8-40E2-89E5-8B5D11FB82A0Q40290852-8B78698A-4DEB-4E30-98B1-B2F16BA87631Q40727658-F2ABD096-BE41-44E6-AA7F-A2FF0B675764Q42432332-32042387-0275-4F09-B3B9-2D9AC5B573EA
P2860
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antipneumococcal activities of ...... le and -resistant pneumococci.
@ast
Antipneumococcal activities of ...... le and -resistant pneumococci.
@en
type
label
Antipneumococcal activities of ...... le and -resistant pneumococci.
@ast
Antipneumococcal activities of ...... le and -resistant pneumococci.
@en
prefLabel
Antipneumococcal activities of ...... le and -resistant pneumococci.
@ast
Antipneumococcal activities of ...... le and -resistant pneumococci.
@en
P2093
P2860
P1476
Antipneumococcal activities of ...... le and -resistant pneumococci.
@en
P2093
Appelbaum PC
Hoellman DB
Pankuch GA
P2860
P304
P356
10.1128/AAC.44.4.1085-1088.2000
P407
P577
2000-04-01T00:00:00Z